DMYD B — Diamyd Medical AB Share News
0.000.00%
Last trade - 00:00- SEK156.53m
- -SEK93.80m
- SEK0.48m
Brief: Diamyd Medical Q2 Net Loss Widens To SEK 25 Mln
Brief: Diamyd Medical Partners With JDRF
Brief: Diamyd Medical Receives Patent Protection In U.S, Japan For Remygen
Brief: Diamyd Medical Q1 Net Loss Narrows To SEK 33.0 Mln
Brief: Diamyd Medical To Be Granted Precision Medicine Patent
Brief: U.S. Partial Clinical Hold On Diamyd® Phase Iii Trial Lifted By The FDA
Brief: Diamyd Medical Q4 Net Loss Widens To SEK 36.7 Mln
Brief: Diamyd Medical: Promising Topline Results For Intralymphatic Diamyd In Patients With LADA
Brief: Diamyd Medical March-May Net Loss Narrows To SEK 17.1 Mln
Brief: Diamyd Medical's Principal Owner Sells 4.5 Million Of Diamyd Medical Shares In Form Of Gifts
Brief: Diamyd Medical Q2 Net Loss Narrows To Sek 9.0 Mln
Brief: Diamyd Medical Proceeds With Initiation Of Type 1 Diabetes Phase III Trial In Europe
Brief: Diamyd Medical Q1 Net Result Turns To Loss Of SEK 37.8 Mln
Brief: Diamyd Medical Patent To Be Granted In China
Brief: Diamyd Medical Gets Patent Granted In Australia
Brief: Diamyd Medical Pauses Start Of Phase III Trial
Brief: Diamyd Medical Q4 Net Loss Widens To SEK 27.4 Mln
Brief: Diamyd Medical And Partners Are Awarded Sek 40 Million In Vinnova Funding For Prevention Of Autoimmune Diseases
Brief: Diamyd Medical Receives First Regulatory Approval To Start Phase III Trial Diagnode-3 With Diabetes Vaccine Diamyd